536-71-0

Basic information

• Product Name: Diminazene
• Synonyms: diminazene;4,4'-(1-triazene-1,3-diyl)bisbenzenecarboximidamide;1,3-bis(4-amidinophenyl)triazene;4,4'-(1,3-Triazenediyl)bis(benzamidine);4,4'-(Azoimino)bis(benzamidine);4,4'-(Diazoamino)dibenzamidine;4-[(4-Amidinophenylazo)amino]benzamidine;4-[2-(4-carbamimidoylphenyl)iminohydrazinyl]benzenecarboximidamide
• CAS NO: 536-71-0
• Molecular Formula: C₁₄H₁₅N₇
• Molecular Weight: 281.3158
• EINECS: 208-644-6
• Product Categories: Pesticide intermediates
• Mol File: 536-71-0.mol
• Article Data: 1

Chemical Properties

• Boiling Point: 463.3 °C at 760 mmHg
• Flash Point: 234 °C
• Appearance: /
• Density: 1.39 g/cm³
• Vapor Pressure: 9.21E-09mmHg at 25°C
• Refractive Index: 1.707
• PKA: 12.11±0.50(Predicted)
• CAS DataBase Reference: Diminazene(CAS DataBase Reference)
• NIST Chemistry Reference: Diminazene(536-71-0)
• EPA Substance Registry System: Diminazene(536-71-0)

Safety Data

• Hazardous Substances Data: 536-71-0(Hazardous Substances Data)

Usage

Description

Diminazene is a triazene derivative with each of the terminal nitrogens substituted by a 4-carbamimidoylphenyl group. It is a pharmaceutical compound known for its specific applications in various industries.

Uses

Used in Pharmaceutical Industry:
Diminazene is used as a chemotherapeutic agent for the treatment of trypanosomiasis, a disease caused by the parasitic protozoa of the genus Trypanosoma. It is particularly effective against the early stages of African trypanosomiasis, also known as sleeping sickness, and is administered to both humans and animals.
Used in Veterinary Medicine:
In the veterinary field, Diminazene is utilized as an antiprotozoal agent for the treatment of various trypanosome infections in animals, such as cattle, sheep, and horses. It helps in controlling the disease and reducing the impact on livestock health and productivity.
Used in Research Applications:
Diminazene is also used as a research tool in the study of trypanosome biology, drug resistance, and the development of new therapeutic strategies against trypanosomiasis. Its application in research contributes to the understanding of the disease and the identification of potential new treatments.

InChI:InChI=1/C14H15N7/c15-13(16)9-1-5-11(6-2-9)19-21-20-12-7-3-10(4-8-12)14(17)18/h1-8H,(H3,15,16)(H3,17,18)(H,19,20)

Synthetic route

diminazene (536-71-0) → 4,4'-dicarbamoyldiazoaminobenzene

Conditions	Yield
With sodium carbonate

Upstream product

• 3858-83-1 p-aminobenzamidine 
• 145855-63-6 diminazene diamidoxime 
• 1093268-26-8 diminazene monoamidoxime 

Downstream Products

• 90738-25-3 Rh₂(O₂CCH₃)3(bis(4,4'-(1-triazene-1,3-diyl)dibenzamidine))dirhodium(II) 
• 90751-75-0 Rh₂(O₂C(CH₂)2CH₃)3(bis(4,4'-(1-triazene-1,3-diyl)dibenzamidine))dirhodium(II) 

Relevant articles and documents

The fourth molybdenum containing enzyme mARC: Cloning and involvement in the activation of N-hydroxylated prodrugs

The recently discovered mammalian molybdoprotein mARC1 is capable of reducing N-hydroxylated compounds. Upon reconstitution with cytochrome b 5 and b5 reductase, benzamidoxime, pentamidine, and diminazene amidoximes, N-hydroxymelagatran, guanoxabenz, and N-hydroxydebrisoquine are efficiently reduced. These substances are amidoxime/N-hydroxyguanidine prodrugs, leading to improved bioavailability compared to the active amidines/guanidines. Thus, the recombinant enzyme allows prediction about in vivo reduction of N-hydroxylated prodrugs. Furthermore, the prodrug principle is not dependent on cytochrome P450 enzymes.